Pediatric Hematology Oncology Unit, Department of Pediatrics, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Pediatr Hematol Oncol. 2024 Nov;41(8):620-632. doi: 10.1080/08880018.2024.2411321. Epub 2024 Oct 12.
Cancer predisposition syndromes (CPS) are a group of genetic disorders that increase the risk of various cancers. Identifying CPS has a significant impact on the treatment plan, screening and follow-up strategy, and genetic counseling of the family. However, in children, it goes underdiagnosed in most clinical setups, especially in low- and middle-income (LMIC) countries. In the present study, we screened 60 pediatric oncology patients for a possible CPS based on pre-defined selection criteria. Six patients met the criteria, three of whom had hematological malignancy, while the remaining three had sarcoma. Whole exome sequencing was performed in the selected patients to confirm the diagnosis. Germline mutation in CPS-related genes was discovered in five of six cases, including novel mutations discovered in two. An adverse outcome was observed in all five patients with underlying cancer predisposition syndrome, with three having relapsed and two having progressive disease. Our study reflects a prevalence of 10% underlying CPS in a limited cohort of patient based on the phenotype-genotype approach in our cohort. Using pre-defined clinical selection criteria, screening can be directed to a high-risk patient cohort with high-pick up rate for CPS. The selection criteria could be utilized in any LMIC-based clinical setup for pediatric cancer patients who may benefit from modification of treatment as well as genetic counseling.
癌症易感综合征(CPS)是一组遗传疾病,会增加各种癌症的风险。识别 CPS 对治疗计划、筛查和随访策略以及家族的遗传咨询有重大影响。然而,在儿童中,大多数临床环境下都存在诊断不足的情况,尤其是在中低收入国家(LMIC)更是如此。在本研究中,我们根据预先确定的选择标准,对 60 名儿科肿瘤患者进行了可能的 CPS 筛查。有 6 名患者符合标准,其中 3 名患有血液恶性肿瘤,其余 3 名患有肉瘤。在选定的患者中进行了全外显子组测序以确认诊断。在 6 例中发现了与 CPS 相关基因的种系突变,其中包括在 2 例中发现的新突变。所有患有潜在癌症易感性综合征的 5 例患者均出现不良预后,其中 3 例复发,2 例疾病进展。我们的研究反映了在基于表型-基因型方法的有限患者队列中,潜在 CPS 的患病率为 10%。使用预先确定的临床选择标准,可以将筛查指向具有高 CPS 检出率的高风险患者队列。这些选择标准可以在任何基于 LMIC 的临床环境中用于儿科癌症患者,以便为他们提供治疗和遗传咨询的修改。